Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PHGDH | O43175 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | BCR | P11274 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22130447 | 0.81 | NOTUM (0.49) | ALDH1A1GAA | |
| SCHEMBL20562239 | 0.76 | RBP4 (0.40) | LMNAPOLBHPGDMAPK8MAPK10 | |
| SCHEMBL22130448 | 0.73 | NPY5R (0.41) | — | |
| SCHEMBL21958768 | 0.69 | LMNA (0.51) | LMNAALDH1A1MAPTGAA | |
| SCHEMBL22130453 | 0.69 | RHOA (0.52) | LMNAPOLBHPGD | |
| SCHEMBL22130461 | 0.69 | RHOA (0.52) | LMNAPOLBHPGD | |
| SCHEMBL22130456 | 0.68 | LMNA (0.43) | LMNAPOLBHPGDMAPK8MAPK10 | |
| SCHEMBL22130459 | 0.68 | RHOA (0.58) | LMNAPOLBHPGD | |
| SCHEMBL22130452 | 0.68 | RHOA (0.58) | LMNAPOLBHPGD | |
| SCHEMBL22130474 | 0.67 | NR3C1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10688080-B2 | Compositions, methods of use, and methods of treatment | UNIVERSITY OF SOUTH FLORIDA (US) | 2020-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10688080-B2 | Compositions, methods of use, and methods of treatment | LIPA, LCT, GAA | LMNA 338/4885POLB 228/4885HPGD 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.